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Process evaluation of the data-driven
quality improvement in primary care (DQIP)
trial: active and less active ingredients of a
multi-component complex intervention to
reduce high-risk primary care prescribing
Aileen Grant1* , Tobias Dreischulte2,3 and Bruce Guthrie3
Abstract
Background: Two to 4% of emergency hospital admissions are caused by preventable adverse drug events.
The estimated costs of such avoidable admissions in England were £530 million in 2015. The data-driven quality
improvement in primary care (DQIP) intervention was designed to prompt review of patients vulnerable from
currently prescribed non-steroidal anti-inflammatory drugs (NSAIDs) and anti-platelets and was found to be effective
at reducing this prescribing. A process evaluation was conducted parallel to the trial, and this paper reports the
analysis which aimed to explore response to the intervention delivered to clusters in relation to participants’
perceptions about which intervention elements were active in changing their practice.
Methods: Data generation was by in-depth interview with key staff exploring participant’s perceptions of the
intervention components. Analysis was iterative using the framework technique and drawing on normalisation
process theory.
Results: All the primary components of the intervention were perceived as active, but at different stages of
implementation: financial incentives primarily supported recruitment; education motivated the GPs to initiate
implementation; the informatics tool facilitated sustained implementation. Participants perceived the primary
components as interdependent. Intervention subcomponents also varied in whether and when they were
active. For example, run charts providing feedback of change in prescribing over time were ignored in the informatics
tool, but were motivating in some practices in the regular e-mailed newsletter. The high-risk NSAID and anti-platelet
prescribing targeted was accepted as important by all interviewees, and this shared understanding was a key wider
context underlying intervention effectiveness.
Conclusions: This was a novel use of process evaluation data which examined whether and how the individual
intervention components were effective from the perspective of the professionals delivering changed care to patients.
These findings are important for reproducibility and roll-out of the intervention.
Trial registration: ClinicalTrials.gov, NCT01425502.
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Background
High-risk prescribing in primary care
High-risk prescribing in primary care is a major concern
for health-care systems internationally. Between 2 and
4% of emergency hospital admissions are caused by
preventable adverse drug events [1, 2]. The National
Institute of Clinical Excellence (NICE) estimated in 2015
that avoidable drug-related admissions in England cost
commissioners £530 million per year [3], and the com-
bined cost of drug-related hospital admissions, emer-
gency department and outpatient visits in the USA was
estimated at $19.6 billion in 2013 [4]. A large proportion
of these admissions are caused by high-risk prescribing of
commonly prescribed drugs, with non-steroidal anti-
inflammatory drugs (NSAIDs) and anti-platelets being the
main or among the main drugs implicated, causing gastro-
intestinal, cardiovascular, and renal adverse events [5–7].
Data-driven quality improvement in primary care (DQIP)
intervention and trial
In the UK, virtually, all primary care prescribing is done by
general practitioners (GPs). The DQIP intervention was
systematically developed and optimised [8–10] and com-
prised three intervention components: (1) professional
education about the risks of NSAIDs and anti-platelets via
an educational outreach visit by a pharmacist, written edu-
cational material, and regular newsletters which also pro-
vided feedback on progress after the practice started the
intervention; (2) financial incentives to review patients at
the highest risk of NSAID and anti-platelet ADEs, split into
a participation fee of £350 and £15 per patient reviewed;
and (3) access to a web-based IT tool (which extracted data
from GP practice systems to measure practice rates of
high-risk prescribing, identify patients for review, bring to-
gether relevant data from different parts of the GP record
to make review easier, and allowed recording of review de-
cisions to ensure appropriate follow-up), to identify such
patients and support structured review. The DQIP inter-
vention was evaluated in a pragmatic cluster randomised
controlled stepped wedge trial [9] in 33 practices from one
Scottish health board, where all participating practices re-
ceived the intervention but were randomised to one of ten
different start dates [11]. The primary outcome of the trial
was a composite of nine NSAID and anti-platelet prescrib-
ing indicators. The trial analysis of the primary outcome
showed that across all practices, the targeted high-risk pre-
scribing fell during the intervention period (from 3.7% im-
mediately before to 2.2% at the end of the intervention
period (adjusted OR 0.63 [95%CI 0.57–0.68], p < 0.0001).
The intervention only incentivised review of ongoing high-
risk prescribing, but led to reductions in both ongoing
(1.5% at end vs. 2.6% pre-intervention, adjusted OR 0.60
[95%CI 0.53 to 0.67], p < 0.001) and ‘new’ high-risk
prescribing (0.7 vs. 1.0%, adjusted OR 0.77 [0.68 to 0.87],
p < 0.001). Notably, reductions in high-risk prescribing
were sustained in the year after financial incentives
stopped. In addition, in trial pre-specified secondary
analysis, there were reductions in emergency hospital ad-
missions with gastrointestinal ulcer or bleeding (from 55.7
to 37.0/10,000 person-years, RR 0.66 [95%CI 0.51–0.86],
p = 0.002) and heart failure (from 708 to 513/10,000
person-years, RR 0.73 [95%CI 0.56–0.95], p = 0.02) [12].
Process evaluation of the DQIP intervention
Descriptions of complex interventions in the research lit-
erature often lack details about the context in which inter-
ventions were delivered and about the delivery and
implementation of individual intervention components
[13–15]. Such details are however important to decide
whether and how an intervention can be implemented in
routine care and to inform future research [14, 15]. Along-
side the main DQIP trial, we therefore carried out a com-
prehensive mixed-methods process evaluation [16, 17]
based on a cluster-randomised trial process-evaluation
framework which we developed [18]. Our framework em-
phasises the importance of considering two levels of inter-
vention delivery and response that often characterise
cluster-randomised trials of behaviour change interventions
(although their relative importance will depend on inter-
vention design). The first is the intervention that is deliv-
ered to clusters, which respond by adopting (or not) the
intervention and integrating it with existing work. The sec-
ond is the change in care which the cluster professionals
deliver to individual patients. In DQIP, the delivery of the
intervention to professionals was pre-defined, intended to
be delivered with high fidelity across all practices and under
the control of the research team, whereas the intervention
delivered to patients was largely at the discretion of prac-
tices, who decided whether and how they reviewed patients
and whether to change prescribing in those reviewed (simi-
lar to most health service interventions of this nature). We
used this framework to structure our parallel process evalu-
ation, mapping data collection to a logic model of how the
data-driven quality improvement in primary care (DQIP)
intervention was expected to work (Fig. 1).
Our process evaluation was also informed by normalisa-
tion process theory which assists exploration how interven-
tions become integrated, embedded, and routinized into
social contexts [19]. Normalisation process theory (NPT) is
a theory of implementation designed to assist interpret-
ation of how interventions or new work practices are
embedded, enacted, and operationalised within healthcare
settings. Interventions or practices become routinely em-
bedded through people working individually or collectively
to enact them. This theory is made up of four constructs:
coherence which refers to participants understanding of the
intervention; cognitive participation which focuses on en-
rolment and engagement with the work; collective action
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focuses on how the work was carried out; and reflexive
monitoring is about how participants assess their progress.
NPT had utility qualitatively in sensitising the research
team to response in relation to whether and how the
intervention was incorporated into practice from the pro-
fessional’s perspective, and quantitatively in designing mea-
sures to assess implementation of the DQIP intervention.
Focus of this paper
The focus of this paper is on practice participant percep-
tions of the intervention delivered by the research team
to participating practices, which had financial incentive,
educational, and informatics components. Complex
interventions which have multiple components are
common, usually because researchers believe that com-
ponents will be complementary in terms of being either
additive in their effect or synergistic (the whole being
greater than the sum of its parts). In the analysis of the
main trial, it is not possible to disentangle which compo-
nents are effective or necessary. The aim of the analysis
reported in this paper was therefore to examine profes-
sionals’ perceptions of, and responses to the multi-
component intervention delivered to practices, and at
which point in recruitment and implementation these
components were perceived as more or less active. The
study was reviewed by the Fife and Forth Valley Research
Ethics Committee (11/AL/0251), and informed consent
was obtained from all participants to participate and to
publish anonymised data.
Methods
The overall design and methods have been described
previously in the published protocol [20]. In brief, the over-
all design was a mixed methods parallel process evaluation
which examined a set of pre-defined processes and their
associations with change in high-risk prescribing at practice
level. The quantitative element examined how change in
prescribing at practice level was associated with practice
characteristics and practice implementation of key pro-
cesses and is reported separately (Process evaluation of the
data-driven quality improvement in primary care (DQIP)
trial: quantitative examination of representativeness of trial
participants and heterogeneity of impact. Submitted). The
qualitative element consisted of comparative case studies in
10 of the 33 participating practices purposively sampled
using maximum variation sampling [21] to include a mix of
those initially responding and not responding to the inter-
vention by rapidly reducing their high-risk prescribing, as
judged by visual inspection of run charts approximately
4 months after practices started the intervention. The case-
Fig. 1 DQIP process evaluation framework. (This paper is reporting column one, the intervention delivered to professionals)
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study analysis of how practices adopted, implemented, and
maintained the intervention is described separately (Process
evaluation of the data-driven quality improvement in pri-
mary care (DQIP) trial: case-study evaluation of adoption
and maintenance of a complex intervention to reduce high-
risk primary care prescribing. Submitted). This paper exam-
ines professional participant perceptions of the multicom-
ponent intervention delivered to practices using qualitative
analysis of interview data collected in the case-study
practices.
In each practice, all interviews were carried out by AG
(a researcher over 10 years of qualitative experience and
already known to two of the practices from a previous
project examining prescribing behaviour) [22] with the
most involved GP and one other GP, the practice man-
ager and any attached primary care pharmacist approxi-
mately 6 months after the practice started the
intervention, and the most involved GP again 9 to
12 months after starting the intervention to explore
changes over time. Interviews were facilitated by a NPT
informed topic guide and lasted approximately 1 h. As
part of the intervention in all practices, the AG accom-
panied the pharmacist (TD) on the educational outreach
visit (EOV) and made field notes detailing attendance
and the practice’s response. Data was gathered between
September 2011 and December 2013 and was in parallel
with the trial to capture changes over time.
The analysis was concurrent and iterative with data gen-
eration allowing issues and themes identified to inform
subsequent data generation and facilitate greater explor-
ation. The analysis continued after data generation until no
new themes emerged. The analysis was carried out by AG
with BG contributing through discussion of data and inter-
pretation until he became aware of the trial results, and
was completed by AG before she knew the outcome of the
trial, meaning that qualitative interpretation was blind to
trial findings and detailed quantitative process evaluation
data. Interview audio-recordings were transcribed verba-
tim. To preserve anonymity, some identifiable details have
been changed and pseudonyms used. A coding frame was
developed inductively from field notes and initial inter-
views and based on our topic guides, framework [18], and
logic model [20]. The constant comparative method facili-
tated revision through detailed analysis [23]. This coding
frame was systematically applied to all data, facilitated by
NVIVO 8. Analysis utilised the framework technique [24]
and NPT as a conceptual framework [19]. AG analysed the
data collected in the study twice, inductively letting
themes emerge from the data and deductively based on
normalisation process theory. NPT interpretation and
coding reliability was established through a workshop with
NPT experts. In this paper, we drew on analysis from the
coherence construct which relates to participant’s percep-
tions of the intervention which was useful in identifying
intervention components from the participant’s perspec-
tive. In our accompanying papers, we present the qualitative
analysis from the remaining NPT constructs: cognitive par-
ticipation, collective action, and reflective monitoring
(Process evaluation of the data-driven quality improvement
in primary care (DQIP) trial: case-study evaluation of adop-
tion and maintenance of a complex intervention to reduce
high-risk primary care prescribing. Submitted) and the quan-
titative data analysis from the NPT informed questionnaires
(Process evaluation of the data-driven quality improvement
in primary care (DQIP) trial: quantitative examination of
representativeness of trial participants and heterogeneity of
impact. Submitted). The data was explored for negative
cases. Practice names have all been anonymised.
Results
The findings presented are from 38 professional interviews
(ten lead GPs of whom nine were interviewed twice, seven
GPs less involved with DQIP, nine practice managers/ad-
ministrators and three practice pharmacists and from ap-
proximately 11 h of field notes from each case study’s EOV
(one practice requested and received the education and
training twice because of initial implementation failure).
Tables 1 and 2 provide a detailed description of the inter-
vention components defined in the published protocol [15,
20] based on the TIDieR checklist [15] with illustrative study
materials provided in the Additional files 1, 2, and 3. The
intervention delivered to practices had three main compo-
nents: (1) financial incentives; (2) education; and (3) a web-
based informatics tool which used data extracted from GP
electronic medical records. Each of these three main compo-
nents had a number of subcomponents, included in the
intervention for a range of rationales which are detailed in
Table 2. Participant’s perceptions of these components and
when they were perceived to have an effect are summarised
in Table 2 and discussed in detail below.
Financial incentive
GPs perceived that the offer of a financial incentive was
important during recruitment since it was recognition of
the additional work to be done in the context of already
stretched work schedules and offered a means of gener-
ating extra income for the practice. The financial incen-
tive was structured with an upfront payment of £350
($600, €440) paid after the EOV and £15 ($25, €19) per
patient reviewed paid after the end of the intervention in
the practice. Most GPs said that the per-patient fee did
not actually change whether or not they reviewed pa-
tients. However, in some practices, sampled for the case
study analysis as early implementation failures (Orosay,
Hellisay and Boreray), the interviewed GP felt increased
awareness of the financial structure or payment could
have facilitated greater implementation of changes in
care for patients. In contrast, GPs in some practices
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which implemented the intervention immediately felt
that DQIP was easy money for work they should already
be doing. One GP went as far as questioning the legitim-
acy of paying GPs for safety work:
“… whether we should be earning for doing that
particular thing I think I would feel a little bit …
mmm, you know, this is something that we should be
picking up on probably without someone dangling a
carrot really …” (Hirta Practice, GP 3 Interview).
Some practices had to be repeatedly reminded to invoice
for the work done, supporting the belief that in at least
some practices, financial incentives played a limited role
in mediating effectiveness even though the offer of pay-
ment helped to get initial engagement during recruitment.
Education
The educational component had several elements; written
material summarising the literature and providing
prescribing advice, tailored newsletters summarising
Table 1 TIDieR description of the intervention (item 2 is shown in Table 2)
Intervention component and subcomponents—materials
(item 3) and procedures (item 4)
Who provided (item 5), how delivered (item 6), where delivered (item 7), when and
how much delivered (item 8), how tailored (item 9)
Financial incentives
Up-front payment £350 (547 USD, 497 EUR) paid to every practice paid by the research team
immediately before practice started the intervention, the same for every practice.
Payment per review £15 (23 USD, 21 EUR) per review completed, paid by the research team after the end
of the 48-week intervention period once the practice submitted an invoice, the same
for every practice.
Education
Branding intervention ‘patient safety’ Research team used the term ‘patient safety’ in all communications with all practices.
Prescribing advice Written by the research team for all practices (not tailored) and communicated and
distributed at EOV on a one page laminated sheet.
Structured written educational material reinforcing EOV Written by the research team for all practices (not tailored) and available
electronically from the tool and distributed at the EOV.
Educational outreach visit (EOV) 1 hour face-to-face meeting held in the practice and delivered by the research team
to a common basic structure, but tailored according to practice interests and
expressed needs (Additional file 1). The EOV summarised the latest research evidence,
provided clear prescribing advice, and included training on the tool.
Discussion about potential process to do the work Discussions facilitated by research team during EOV tailored to specific practice
characteristics and wishes.
Newsletters The research team sent a practice progress report to the lead GP and practice
manager 8 weekly both before the practice started the intervention (non-tailored
update on the progress of the trial and a reminder of the practice start date) and
during the intervention period (tailored to reflect practice progress by providing a
run chart, commentary on practice progress including comparison to other practices
at the same point in implementing the intervention, and offers of further support)
(Additional file 2).
Informatics tool
Identification of patients to review Web-based tool hosted by NHS Tayside, and the same for every practice. Updated
weekly using data-extracted from the general practice’s own clinical records.
Practice’s had controlled access through personal log in details via the NHS intranet.
At log-in, an updated list of patients needing review was available (Additional file 3:
Appendix Figures A1 and A3).
Summarise clinical information to facilitate review The web-based tool provided a structured summary of relevant patient clinical
information to facilitate review (summarised risk factors for relevant adverse drug
effects, summary of recent relevant prescribing, Additional file 3: Appendix Figure A4).
Recording of review decisions
Run charts of change in prescribing GPs were required to record their review decisions within the informatics tool in
order to receive payment (Additional file 3: Appendix Figures A4 and A5. This
information was used to ensure that reviewed patients where prescribing was
judged appropriately were not repeatedly flagged for review (to increase efficiency
by avoiding pointless re-review) except where prescribing judged inappropriate was
restarted (to ensure follow-up of patients where intended care was not delivered).
Timely visual feedback of progress (also used in 8 weekly newsletters in ‘education’)
tailored for reach practice and available to view at any time within the informatics
tool (Additional file 3: Appendix Figure A2).
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practice progress and offering support, and an EOV which
both targeting knowledge and attitudes, and facilitated
discussion of how practices were going to organise to do
the DQIP work. All of these and the initial recruitment
material were designed so that they clearly branded the
work as being about patient safety.
Branding as patient safety and the NSAID and anti-platelet
topic
Generally, participants in practices in the process evalu-
ation said they signed up to the DQIP trial because they
perceived that prescribing safety was clearly about good
patient care and was therefore work they should be
Table 2 Summary of the active and less active components of the DQIP intervention
Intervention component and subcomponents Research team’s rationale(s) for including this
component (TIDieR item 2)
Participant’s perceptions and/or use of the
intervention components
Financial incentives
In general Attract practices to participate Important for recruitment as symbolised
recognition of the additional work required of
GPs and generated extra income.
Up-front payment Increase practice commitment to doing the
work as already accepted some payment
Had a limited role in mediating effectiveness.
Payment per completed review Ensure reach is maximised and work is
maintained over trial duration
Practices said the financial incentive did not
change what they did but two failing practices
said had they known about the financial
incentive they may have done more.
Education
Branding DQIP patient safety Motivate GPs by appealing to their professional
values
Important for recruitment as most GPs felt they
could not ignore this topic.
Prescribing advice Avoid inertia Had an important role in mediating
effectiveness because GPs valued clear and
concise prescribing advice and were able to
action decisions quickly.
Structured written educational material
reinforcing EOV
Support and reinforce the educational messages
delivered in the EOV
No perceived role in effectiveness. Two GPs
used the one page laminated sheet when
communicating with patients. Otherwise, this
material was not referred to.
Educational outreach visit Persuade the GPs that the prescribing mattered
and encourage GPs to perceive this as new and
necessary work which required immediate
attention
Had a limited role in mediating effectiveness
because already persuaded GPs said they did
not find the messages ‘new’, and the already
less convinced GPs were not always persuaded
that this was a problem worthwhile addressing.
Discussion about potential process to do the
work.
Motivate GPs to commence review immediately. Had an important role in large practices for
identifying an appropriate process and defining
roles and responsibilities.
Newsletters Aimed to encourage continued reviewing
activity.
Encouraged non-reviewers to revisit tool. Re-
viewers liked seeing their high risk prescribing
going down.
Informatics
Identification of patients to review Mobilise GPs to review by reducing
administrative burden (at the time of the trial
this was a labour intensive process primarily
conducted by pharmacists and administrative
staff).
Important for implementing change as GPs
valued the tool’s simple case finding ability and
did not question its accuracy.
Structured clinical information to facilitate
review
Facilitate efficient reviews by providing relevant
information (reviewing was time consuming as
involved reading patient’s notes to identify
relevant information).
Important for effectiveness as GPs legitimised
and valued the relevant and accurate data;
however, all GPs continued to consult patient’s
clinical notes.
Record review decisions Record data important for the trial and process
evaluation.
Some GPs found the requirement to ensure all
relevant information was addressed irritating.
Run charts of change in prescribing Motivate GPs to continue reviewing by
comparison to previous performance
Had a limited role mediating effectiveness
because GPs were not generally motivated by
this in the web-based tool, although the same
run charts were motivating for some when sent
in newsletters.
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doing. GPs said that the NSAID and anti-platelet topics
covered by DQIP were well-known safety issues, and the
logic of the trial resonated with messages they had re-
ceived from other sources, such as in Health Board orga-
nised ‘protected learning time’ educational sessions and
from their practice pharmacist. As a result of this shared
understanding, they perceived that their practice re-
quired good justification for not signing up for an inter-
vention which targeted a well-known patient safety risk
and paid them to do so. This high legitimation of the
work also facilitated implementation of the intervention
in all but four practices which took part in the trial and
facilitated expeditious implementation in some practices.
“I felt this was actually genuinely useful, and of
benefit to the patients… we’ve always had a bit of an
interest in prescribing actually and quite enjoyed
some of the little projects that we’ve done with the
pharmacist…he is supporting this because it covers
some of the issues we’ve already covered but in less
detail.” (Monach Practice, GP 1 interview)
Prescribing advice, structured written educational
material and educational outreach visit
The summary of the literature and educational material
aimed to improve knowledge and motivate GPs to carry
out the reviews. This was valued because it provided
clear and up-to-date recommendations, brought the lat-
est evidence and recommendations to the fore of their
minds and aided consistent prescribing behaviour.
… it, it was good, there were references that you
could go away along and, and read if you wanted …
that’s one of the benefits of these things, is if
somebody’s done the research and presents it to you
and we’re all singing from the same Hymn sheet.”
(Hirta Practice, GP 1 interview)
However, these messages were not viewed as ‘new’, and
although participants valued the educational material,
they did not refer to it while delivering care to patients,
perhaps reflecting that its messages were easily interna-
lised. These views were consistent across all participants
in the process evaluation. Participants contrasted this
summary material with what was normally provided dur-
ing other improvement activities, which was typically
longer, less focused and perceived as being less useful.
Overall, the EOV was viewed by interviewees as useful
but not essential (see Additional file 1 for the presenta-
tion used). They felt it was useful to have a verbal sum-
mary of the literature and recommendations and an
overview of the DQIP tool, but these were not felt to be
essential to implementing effective reviews. Consistent
with this, some GPs who led on delivering their
practice’s reviews using the tool did not attend the EOV.
Interestingly, one practice (Orosay Practice) which failed
to implement the DQIP intervention by not conducting
any reviews using the tool still observed a reduction in
the targeted prescribing, potentially because of an effect
from the educational material.
“Yeah it’s been because of DQIP really yes, aye. Well I
suppose we were always anxious prescribing in the
elderly… eh, but it’s merely made me sit up and pay a
bit more attention…
AG: when you see the patient’s name on the tool or
now more generally are you better informed?
It’s more now when I see them, and I didn’t even
know if their name’s on the tool …em it’s more of
when I see them and I see that they’re on it (NSAID
or antiplatelet).”(Orosay Practice, GP 1 interview)
Discussion about potential process to do the work
During the EOV, practices were offered the opportunity
discuss the ‘best’ process by which they could manage
the work load. For some practices, these discussions
played an important role in defining how they would or-
ganise the work, including roles and responsibilities.
These discussions ensured the work commenced shortly
after the EOV in the large initial implementation
practices where administrative staff were given a co-
ordinating role (Taransay and Hirta Practices), but were
of less value in small practices where the intervention
was being delivered by fewer people.
“…we started immediately…a list is issued by
(administrative staff member named), em to whoever
perceived to be the em doctor who sees most of that
patient to action it each week, and then it’s, the boxes
are ticked and it’s gone back to them to compute.”
(Taransay Practice, GP 1 interview)
Newsletters
Newsletters, summarising practice performance using data
from the tool, were sent to practices at eight weekly inter-
vals. They were circulated around GPs in most practices,
but were not formally discussed in any practice participat-
ing in the process evaluation (an example is shown in
Additional file 2). In practices which immediately imple-
mented DQIP, GPs felt the newsletters were nice to receive
to see their targeted ‘high-risk’ prescribing reducing. In two
small practices, with immediate implementation, the GPs
responsible for the review work found the run charts show-
ing practice progress motivating. Similarly, in two of the
practices which initially did not implement the
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intervention, GPs felt the newsletters were motivating and
pushing them into revisiting the tool and review
medication.
“Oh yes! Yes we did … yeah we did, em … yeah it kind
of pushed us into doing it (reviewing prescribing)…
when we got the monthly newsletter.” (Hellisay
Practice, GP 2 Interview)
Informatics tool
In order to be paid, GPs had to use the informatics tool to
record review decisions. The tool provided feedback on
changes over time in targeted prescribing (run charts),
identified patients requiring a review, supported review by
summarising relevant clinical information extracted from
multiple areas of the GP clinical record, and allowed re-
cording of review decisions which then determined
whether and when the patient would be identified as
needing review again. Although some practices initially
intended to use a print out of identified patients to do re-
views, all but one GP carried out the medication reviews
online using the tool (see Additional file 3, for example,
screenshots). All GPs found the tool intuitive, straightfor-
ward and well structured, as the quote below illustrates:
“I liked it — I think we both did — it was, it was easy
to use, it was intuitive, you didn’t need a half day
tutorial on how to use the blessed thing.”
(Hellisay Practice, GP 2 Interview)
The tool’s case finding ability was particularly attractive,
especially identifying historical risk factors which GPs felt
they were likely to overlook when carrying out a medica-
tion review using the same data in their own electronic
medical record (e.g. previous peptic ulcer). The GPs also
valued the focused data presentation, which only displayed
information relevant to the prescribing decision.
“…it’s very straightforward in that you have the
on-line tool and it gives you a very structured way of
doing it which is, once you get into it much quicker,
and other stuff that we do for the sort of GMS and
the quality, the National Quality indicator things, em
all involve us having to go in and do searches and find
people and you know a lot of it’s done on bits of
paper and things, so it, it’s done but it’s not, it’s not as
easy, it’s, it’s actually made doing this really quite
simple and that the tools you know, searches for the
patients for you and things which is really good.”
(Mingulay Practice, GP 2 Interview)
Although GPs were very positive about the tool, they
would prefer a tool which was able to write to their
clinical records to prevent double entry of review deci-
sions, for example:
“I think it would be great, the only thing that would be
really, really good is if it could talk to Vision [the clinical
IT system]…” (Mingulay Practice, GP 1 Interview)
The majority of GPs also expressed a desire for a real-
time intervention triggered by an alert when the patient
consulted:
“…at the time of the prescription being done rather
than retrospectively looking back at it, so that the
prescription’s not issued in the first place, might be a
good idea.” (Monach Practice, GP1 Interview)
However, a number of GPs preferred a DQIP-like
intervention which retrospectively corrected prescribing,
because they felt consultations were already heavily time
constrained and preferred reviewing outside of clinical
consultation to allow sufficient time to adequately re-
view medication.
“Correcting past behaviour … that can make it … it’s a
bit of a frustration but I can’t see how it would be
otherwise really in the sense that, I don’t know how
you fancy an alarm going off every time you sort of
try to prescribe something…” (Gighay Practice,
GP 1 Interview)
There were no differences in opinion about the in-
formatics tool between professionals in practices which
initially responded to the intervention delivered to them
and those who did not.
Performance graphs (run charts)
Within the informatics tool were run charts of change in
high-risk prescribing over time where practices could re-
view their progress. These depicted the trend in their
targeted high-risk prescribing 2-years pre-DQIP and
since they started receiving the DQIP intervention. The
run charts in the tool were not perceived to be of value
by most GPs due to the relatively small number of pa-
tients identified in most practices, although as described
above, the same run charts in the newsletters were mo-
tivating in some practices.
Although the component parts of the DQIP interven-
tion were important at different stages of recruitment and
delivery of the intervention, they also had interactions
which were important for effective delivery and imple-
mentation. Consistent branding of the DQIP intervention
and the financial component ensured GPs were on-board
and engaged, the educational component provided clear
messages which helped ensure consistency when making
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prescribing decisions using the tool, and the newsletters
provided feedback and motivation to ensure engagement
was maintained.
Discussion
Our findings have shown that all primary components of
the intervention were ‘active’, but at different stages. The
financial incentive was perceived as most important dur-
ing recruitment because it acknowledged the additional
work required and offered a means of generating extra
income. The education including the focus on patient
safety reflected in the way the work was branded, moti-
vated the GPs to prioritise this work during initial imple-
mentation, and was valued because it provided clear and
concise prescribing advice. Notably, many GPs perceived
that some or all of the elements of education were useful
but not essential, but individuals varied in terms of
which elements they valued most. The informatics tool
was crucial in case-finding patients, in facilitating effi-
cient medication review decisions, and in implementing
the required changes. Many GPs expressed a desire for a
real-time alerting element to the informatics as well as
support for retrospective review (although it is import-
ant to recognise that the majority of the targeted indica-
tors would have triggered an interaction alert at the
point of prescribing, consistent with point of care re-
minders not being a panacea in this area).
Overall, all respondents perceived that some of the
components and sub-components were active and syner-
gistic, but there was a variation between participants in
which were most valued or perceived to be most active.
There was therefore no clearly or consistently identified
set of inactive components, and our interpretation is
that this suggests that all component parts should be de-
livered in any further roll-out. However, our prior expec-
tations of how and when different components would be
active were not always correct. In particular, financial in-
centives were perceived by participants as less important
than we anticipated, being active in recruitment and ini-
tial engagement, but not in promoting sustained delivery
to all eligible patients (notwithstanding the caveats de-
scribed above about how professionals might talk about
such incentives in interviews). Although, the run charts
and newsletters presented the same data, the run charts
providing feedback on progress in the informatics tool
were rarely looked at whereas the newsletters were val-
ued in some practices possibly because the latter were
accompanied by some individualised interpretation,
emphasising that delivery mechanisms matter as well as
what is being delivered. This is consistent with the wider
audit and feedback literature which emphasises that
feedback needs to be optimised to context to maximise
effectiveness, although this study was not designed to
examine this directly [25].
It is important to note that professional interview data
about financial incentives can be difficult to interpret,
since some professionals may find it morally ambiguous
to say that they require money to improve safety, making
it more likely that they say that the incentives did not
alter their actions. Nevertheless, some practices had to
be repeatedly reminded to invoice for the work done,
supporting the belief that in at least some practices,
financial incentives played a limited role in mediating
effectiveness even though the offer of payment helped to
get initial engagement during recruitment.
It is also worth noting that the targeted prescribing
topic and intervention were intertwined, in that partici-
pants were already mostly persuaded that the targeted
prescribing was risky, and their perceptions of the inter-
vention components have to be understood in this con-
text. One implication is that the same intervention
components might not be as effective if targeting a pre-
scribing topic that GPs did not perceive as important, or
which they felt was less under their control. This is con-
sistent with the findings of a trial of a much simpler
feedback intervention in Scotland where five of the tar-
geted measures were similar to DQIP and reduced, but
the sixth measure targeting anti-psychotic prescribing in
older people was unaffected by the intervention [26].
The normalisation process theory construct of coher-
ence was useful in identifying and describing the compo-
nents and sub-components of the intervention and
when they were useful from the perspective of those
who had engaged in some from with the DQIP interven-
tion. For the analysis presented in this paper, we found
normalisation process theory to be useful in understand-
ing the nuances associated with collective implementa-
tion of the DQIP intervention in general practices where
much clinical work is shared.
This study has a number of limitations. The GPs and
practices which participated in this study are a sample of
approximately a third of the whole trial population and
were sampled as outliers at both ends of the distribution
of initial success in reducing prescribing, so their views
may not be truly representative. Data collection and ana-
lysis were carried out by a researcher (AG) who had
involvement in the development of the intervention al-
though the researcher with primary responsibility (TD)
for the intervention development and the trial had no
input into analysis and interpretation of this study. AG
did have discussions with BG about the data analysis
and interpretation. BG is responsible for the research
programme grant, meaning that analysis had limited ex-
ternal scrutiny and challenge.
The analysis in this paper has focused on overall per-
ceptions of when and how different components of the
intervention were effective, but the accompanying case
study paper (Process evaluation of the data-driven
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quality improvement in primary are (DQIP) trial: case-
study evaluation of an complex intervention to reduce
high-risk primary care prescribing. Submitted) qualita-
tively examining variation between practices in more de-
tail indicates that this plays out variably in different
practices, although variation in implementation is also
significantly driven by variability in the barriers experi-
enced. The quantitative analysis reported in the second
accompanying paper (Process evaluation of the data-
driven quality improvement in primary care (DQIP) trial:
quantitative examination of representativeness of the
trial participants and heterogeneity of impact. Submit-
ted). Found that 30/33 practices had at least some re-
duction in high-risk prescribing, which is consistent
with the finding in this paper that all involved profes-
sionals perceived that some or all of the intervention
components were active.
In the wider literature, the DQIP intervention is most
like the intervention evaluated in the pharmacist-led in-
formation technology intervention for medication errors
(PINCER) trial [27]. Important differences were that
PINCER targeted a broader range of prescribing topics
than DQIP, that it was delivered over 12 weeks by phar-
macists, and that it was more standardised in terms of
how the pharmacists carried out medication reviews.
However, the PINCER process evaluation did not expli-
citly examine the subcomponents of the intervention
[28]. A systematic review of main trial evaluations of
pharmaceutical and non-pharmaceutical interventions
found evaluations of non-pharmaceutical interventions
are significantly less likely to list ‘active ingredients’
(those elements of the intervention intended to lead to
change in the outcome, [29], and we have not been able
to identify any other process evaluations of cluster-
randomised trials of multicomponent complex interven-
tions which have examined the ingredients of complex
interventions (although such studies are not easy to find
because of poor labelling and reporting of process evalu-
ations more generally) [17, 18].
Conclusions
This paper provides both a detailed description of the
DQIP intervention delivered to practices to motivate
and facilitate the intended change in how they delivered
care to patients. It uses the TIDieR framework to struc-
ture intervention description [15] and examines where
and when the intervention components were more and
less active. We show that all components of the inter-
vention were active but at different stages of recruitment
and delivery of the intervention, and that components
were perceived to be interdependent and synergistic in
their effects. These findings are important for informing
wider implementation, since they facilitate reproducibil-
ity. More broadly, we believe that trials of complex
interventions should at a minimum report the details of
their intervention using a framework such as TIDieR to
provide a detailed description of the intended active
ingredients of the intervention, but should ideally aim to
examine whether and when each of these the chosen
ingredients is actually active from the perspectives of the
intervention targets.
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